Several blood tests have been shown to diagnose accurately Alzheimer’s disease – As previously reported by Fox News Digital – but now there are new tests that can measure how far it has progressed.
The study was published Monday in the Journal of Natural Medicine and was led by researchers from Washington University School of Medicine in St. Louis and Lund University in Sweden.
Determining the clinical stage of dementia helps to ensure that patients receive the most Beneficial treatmentAccording to researchers.
Alzheimer’s disease-related dementia can be prevented with experimental drugs, researchers say
New tests can also help you see if Alzheimer’s disease or another condition is causing symptoms in a person.
Researchers say new blood tests have emerged that can measure how advanced Alzheimer’s disease has progressed. (istock)
The researchers analyzed blood samples from 163 people experiencing various levels of cognitive decline, ranging from symptoms to early to late dementia.
They found that levels of a protein called Mtbr-Tau243 correlate with the amount of tau accumulated in the brain, according to a Washu press release. The accuracy was 92% compared to brain scans.
The more tau buildup, the more severe the symptoms of Alzheimer’s disease.
MTBR-TAU243 levels were normal in people who had not yet had symptoms. This indicates that proteins are associated with more advanced stages.
Additionally, levels in people whose symptoms were associated with other causes besides Alzheimer’s disease were normal.
What do you know about Tau
Tau is a protein that, by health line, forms “tangles” in the brains of people with Alzheimer’s disease. These tangles interfere with cognitive function.
Tau usually forms several years after the formation of another protein called amyloid, creating plaques in the brain, and is one of the first features of Alzheimer’s disease.
The higher the amount of tau buildup, the more severe the symptoms of Alzheimer’s disease. This was 200 times more symptoms than later stages of dementia.
PET (positron emission tomography) brain scans are now the norm for staging, but researchers noted that they have several drawbacks. (istock)
“Amyloid plaque and tau work together to define the basics Biological brain changes With the disease of Alzheimer’s disease, the loss of brain cells and synapses, “Dr. Courtney Croske, director of scientific engagement at the Alzheimer’s Disease Association in Chicago, told Fox News Digital.
Previously developed blood tests measure levels of amyloid plaque in the brain, the first to measure tau levels.
Two Alzheimer’s drugs help patients live independently at home for longer
“We have seen advances in amyloid blood tests to help with early detection, which has been shown to be extremely accurate and can now be used to assist clinicians in detailed diagnostic testing,” Kloske said.
“The current study is examining the accuracy of Tau blood tests. Once these blood tests have been developed, confirmed and validated, both tests strongly confirm Alzheimer’s disease as a cause of dementia in humans. Treatment Options. ”
“This blood test clearly identifies the Taurus of Alzheimer’s, which is our best biomarker measure of symptoms and dementia from Alzheimer’s,” the researchers said. (istock)
Co-authors Randall J. Bateman, Charles F., Maryland, Joanne Knight, noted Wash Medicine’s professor of neurology. Clinical treatment Today there are no easy or accessible measures of Alzheimer’s disease or dementia.
“This blood test clearly identifies the Taurus of Alzheimer’s, which is our best biomarker measure of Alzheimer’s symptoms and dementia,” he said at his release.
“This intertwined blood test can provide much better indications if the symptoms are caused by Alzheimer’s disease and can help doctors decide the best treatment for their patients.”
Looking ahead
We hope that this new blood test will facilitate Alzheimer’s patients and facilitate treatment tailored to their individual needs.
Click here to get the Fox News app
PET (Positron Emission Tomography) Brain scan Currently, the standard for staging has some drawbacks, researchers have noted.
They are “expensive, time-consuming and often unavailable outside of major research centres,” limiting their use.
“In the early stages where tau tangles are less, anti-amyloid therapy may be more effective than later stages. However, it may be more effective after the onset of dementia with high tau tangles, anti-tau therapy, or one of many other experimental approaches,” the researchers said. (AP Photo/Evan Vucci, file)
“We are about to enter the age of personalised medicine because of Alzheimer’s,” said Dr. Kanta Holly, Associate Professor of Neurology Research at Wash Medicine during his release.
Click here to sign up for our health newsletter
“In the early stages where tau tangles are less, anti-amyloid therapy may be more effective than later stages. However, it may be more effective after the onset of dementia with high tau tangles, anti-tau therapy, or one of many other experimental approaches.”
“In addition to clinically available blood tests for staging, treatments working at different stages of the disease allow physicians to optimize treatment plans for each patient’s specific needs.”
“We are about to enter the age of personalized medicine because of Alzheimer’s.”
Kloske reiterated the need Further research.
“This study is promising for earlier detection methods, but it is necessary to look at the replicating and expansion of these results in larger and representative study populations to understand the impact of the general population,” she told Fox News Digital.
Visit us for more health articles www.foxnews.com/health
The study was funded by Charles F. and Joanne Knight Center for Alzheimer’s Disease Research, Tracy Family Silk Center, National Institutes of Health (NIH), the Zenith Award of the Alzheimer’s Disease Association, the Center for Hope Neuropathy, and the Faculty of Neurology in Wash Medicine.
